The demand for onychomycosis treatment in USA is projected to grow from USD 2.4 billion in 2026 to USD 3.8 billion by 2036, at a CAGR of 4.7%. Drugs will dominate with a 66.0% market share, while distal subungual onychomycosis will lead the indication segment with a 48.0% share.